To include your compound in the COVID-19 Resource Center, submit it here.

Hy BioPharma, Soligenix deal

Soligenix acquired SGX301 from Hy BioPharma for up to $14 million, of which about 2% is payable

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE